Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany

[1]  B. Hemmer,et al.  CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date , 2019, Expert opinion on biological therapy.

[2]  The United States Food and Drug Administration , 2019, Cobert's Manual of Drug Safety and Pharmacovigilance.

[3]  L. Kappos,et al.  Anti‐inflammatory disease‐modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study , 2018, European journal of neurology.

[4]  R. Marrie,et al.  A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry , 2018, Multiple sclerosis.

[5]  G. Comi,et al.  Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management , 2018, European journal of neurology.

[6]  J. Ross,et al.  Characterizing expanded access and compassionate use programs for experimental drugs , 2017, BMC Research Notes.

[7]  G. Comi,et al.  Survey of diagnostic and treatment practices for multiple sclerosis in Europe , 2017, European journal of neurology.

[8]  Bernhard Hemmer,et al.  Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis , 2017, The New England journal of medicine.

[9]  A. Traboulsee,et al.  Ocrelizumab versus Interferon Beta‐1a in Relapsing Multiple Sclerosis , 2017, The New England journal of medicine.

[10]  G. Balasubramanian,et al.  An overview of Compassionate Use Programs in the European Union member states. , 2016, Intractable & rare diseases research.

[11]  Masoume Nazeri,et al.  Association Between Urinary Symptoms and Urinary Tract Infection in Patients With Multiple Sclerosis , 2015, Global journal of health science.

[12]  D. Arnold,et al.  Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity? , 2012, Acta Neuropathologica.

[13]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[14]  P. Calabresi,et al.  Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial , 2009, Annals of neurology.

[15]  H. Hartung,et al.  Bleak prospects for primary progressive multiple sclerosis therapy: Downs and downs, but a glimmer of hope , 2009, Annals of neurology.

[16]  David Green,et al.  Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. , 2009, Blood.

[17]  David H. Miller,et al.  Primary-progressive multiple sclerosis , 2007, The Lancet Neurology.

[18]  N. Téllez,et al.  Ocrelizumab: its efficacy and safety in multiple sclerosis. , 2018, Revista de neurología (Ed. impresa).

[19]  M. Filippi,et al.  Primary Progressive Multiple Sclerosis , 2002, Topics in Neuroscience.